Bolt Biotherapeutics, INC Form 4 insider transactions

William P. Quinn, President, CEO, and CFO of Bolt Biotherapeutics, acquired 440,000 stock options on July 23, 2024.

Sarah Nemec, VP of Finance and PAO at Bolt Biotherapeutics, acquired stock options for 140,000 shares on July 23, 2024.

Director Mahendra Shah acquired 22,000 stock options in Bolt Biotherapeutics on June 12, 2024.

Nicole Onetto, a director of Bolt Biotherapeutics, acquired 22,000 stock options on June 12, 2024, exercisable at $0.7682 per share.

Brian O'Callaghan, a director at Bolt Biotherapeutics, reported the acquisition of stock options for 22,000 shares on June 12, 2024.

Director Frank D. Lee acquired 22,000 stock options in Bolt Biotherapeutics, Inc. on June 12, 2024.

Director Kathleen Laporte acquired 22,000 stock options in Bolt Biotherapeutics on June 12, 2024, at an exercise price of $0.7682.

Director James Healy acquired 22,000 stock options in Bolt Biotherapeutics on June 12, 2024, at an exercise price of $0.7682.

Laura Berner, a director of Bolt Biotherapeutics, acquired 22,000 stock options on June 12, 2024, at an exercise price of $0.7682.

Grant Yonehiro, Chief Business Officer of Bolt Biotherapeutics, acquired 235,000 stock options on March 4, 2024, at an exercise price of $1.27.

Edith A. Perez, Chief Medical Officer of Bolt Biotherapeutics, acquired 235,000 stock options on March 4, 2024, according to a recent SEC filing.

CEO Randall Schatzman of Bolt Biotherapeutics acquired 654,000 stock options on March 4, 2024, while disposing of 235,000 shares.

William P. Quinn, CFO of Bolt Biotherapeutics, acquired 235,000 stock options on March 4, 2024, according to a Form 4 filing with the SEC.